Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Revolution Medicines, Inc. Director's Dealing 2021

Mar 9, 2021

30695_dirs_2021-03-08_eb8a87eb-475c-4d0b-b379-42acf3cfcbc5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-03-04

Reporting Person: GOLDSMITH MARK A (Director, See Remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-03-04 Common Stock A 48000 Acquired 48744 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-04 Stock Option (Right to Buy) $42.45 A 169000 Acquired 2031-03-03 Common Stock (169000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 37032 Indirect
Common Stock 37032 Indirect
Common Stock 266506 Indirect

Footnotes

F1: Includes 48,000 Restricted Stock Units.

F2: Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

F3: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F5: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.